Literature DB >> 23182626

Approaching the era of personalised therapy for liver cancer?

Ghassan K Abou-Alfa1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23182626     DOI： 10.1016/S1470-2045(12)70519-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  3 in total

1.  Curcumin effectively inhibits oncogenic NF-κB signaling and restrains stemness features in liver cancer.

Authors:  Jens U Marquardt; Luis Gomez-Quiroz; Lucrecia O Arreguin Camacho; Federico Pinna; Yun-Han Lee; Mitsuteru Kitade; Mayrel Palestino Domínguez; Darko Castven; Kai Breuhahn; Elizabeth A Conner; Peter R Galle; Jesper B Andersen; Valentina M Factor; Snorri S Thorgeirsson
Journal:  J Hepatol       Date:  2015-05-01       Impact factor: 25.083

2.  The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.

Authors:  Andreas Geier; Rocio I R Macias; Dominik Bettinger; Johannes Weiss; Heike Bantel; Daniel Jahn; Ruba Al-Abdulla; Jose J G Marin
Journal:  Oncotarget       Date:  2017-02-28

3.  Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study.

Authors:  Xue-Fen Lei; Yang Ke; Tian-Hao Bao; Hao-Ran Tang; Xue-Song Wu; Zhi-Tian Shi; Jie Lin; Zhi-Xian Zhang; Hou Gu; Lin Wang
Journal:  World J Clin Cases       Date:  2018-05-16       Impact factor: 1.337
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.